Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Bevacizumab in Recurrent Ovarian Cancer

April 26th 2018

Approaching Recurrent Ovarian Cancer

April 26th 2018

Biomarkers and Molecular Testing in Ovarian Cancer

April 26th 2018

I-O Therapy in Advanced Ovarian Cancer

April 26th 2018

Maintenance Therapy in Ovarian Cancer: PARP Inhibitors

April 26th 2018

Bevacizumab in the Neoadjuvant Setting of EOC

April 26th 2018

Incorporating Bevacizumab into First-Line Practice for EOC

April 26th 2018

Upfront Bevacizumab in Advanced Ovarian Cancer

April 26th 2018

HIPEC in Advanced Ovarian Cancer

April 26th 2018

Adopting Neoadjuvant Therapy into Ovarian Cancer

April 26th 2018

Addressing Limitations in EGFR Exon 20-Mutant NSCLC

April 25th 2018

Personalizing Therapy for EGFR Exon 20-Mutant NSCLC

April 25th 2018

Further Research Investigating Poziotinib in NSCLC

April 25th 2018

Poziotinib Data in EGFR Exon 20-Mutant NSCLC

April 25th 2018

Targeted Therapy in EGFR Exon 20-Mutant Non-Small Cell Lung Cancer

April 25th 2018

Burden of EGFR Exon 20 Mutation in NSCLC

April 25th 2018

Dr. Yu on Treatments for EGFR-Mutant Lung Cancer

April 23rd 2018

Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.

Final Insight: PARPs and gBRCA in Breast Cancer

March 30th 2018

Testing for Germline BRCA Mutations in the Future

March 30th 2018

PARP Inhibitors in Other Subtypes of Breast Cancer

March 30th 2018